Generic Medicine Info
Hypersensitivity to eletriptan. Known or suspected ischaemic heart disease (e.g. angina pectoris, MI, silent ischaemia), coronary artery vasospasm (e.g. Prinzmetal variant angina), severe or uncontrolled HTN, Wolff-Parkinson-White syndrome or arrhythmias, heart failure, previous CVA or TIA, peripheral vascular disease, ischaemic bowel disease, basilar or hemiplegic migraine. Severe hepatic and renal impairment. Concomitant admin w/ 5-HT<209>1<109> receptor agonists or ergot alkaloids.
Special Precautions
Patient at risk of coronary artery disease (e.g. HTN, DM, hypercholesterolaemia, smoker or user of nicotine therapy, post-menopausal women, men >40 yr, strong family history of coronary artery disease, obesity). Mild to moderate renal impairment. Pregnancy and lactation.Patient Counselling This drug may cause dizziness, somnolence, or weakness, if affected, do not drive or operate machinery.Monitoring Parameters Determine a clear diagnosis of migraine before treatment. Monitor CV status prior initiation of treatment and periodically thereafter; hepatic and renal function. Perform periodic CV evaluation for patients w/ risk factors for coronary artery disease who are receiving intermittent long-term therapy.
Adverse Reactions
Significant: Medication overuse headache (MOH). Rarely, elevation in BP (e.g. hypertensive crisis). Nervous: Headache, seizure, asthenia, paraesthesia, dizziness, somnolence, weakness. CV: Chest pain, palpitations, tachycardia, flushing. GI: Dry mouth, nausea, dyspepsia, dysphagia, abdominal pain, vomiting. Others: Weakness.
Potentially Fatal: Cardiac rhythm disturbances (e.g. ventricular tachycardia or fibrillation), MI, coronary artery vasospasm, cerebral or subarachnoid haemorrhage, stroke, peripheral vascular ischaemia, GI vascular ischaemia, infarction, Raynaud's syndrome, anaphylactic reactions (e.g. angioedema).
Drug Interactions
Increased peak plasma concentration w/ potent CYP3A4 enzyme inhibitors (e.g. ketoconazole, clarithromycin, ritonavir). Potential risk of serotonin syndrome w/ SSRIs or serotonin norepinephrine reuptake inhibitors (SNRIs).
ATC Classification
N02CC06 - eletriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.
Disclaimer: This information is independently developed by CIMS based on eletriptan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in